This company has been marked as potentially delisted and may not be actively trading. Most-Downgraded StocksMost-DowngradedNASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Blueprint Medicines Stock (NASDAQ:BPMC) 30 days 90 days 365 days Advanced Chart Get Blueprint Medicines alerts:Sign Up Key Stats Today's Range$129.46▼$129.4650-Day Range$127.95▼$129.4852-Week Range$73.04▼$129.65VolumeN/AAverage Volume1.55 million shsMarket Capitalization$8.36 billionP/E RatioN/ADividend YieldN/APrice Target$130.00Consensus RatingHold Company Overview Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Read More Blueprint Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreBPMC MarketRank™: Blueprint Medicines scored higher than 10% of companies evaluated by MarketBeat, and ranked 906th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingBlueprint Medicines has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 16 hold ratings, and no sell ratings.Amount of Analyst CoverageBlueprint Medicines has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 27.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BPMC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BPMC. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Blueprint Medicines this week, compared to 8 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $640,491.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Stock News HeadlinesBlueprint Medicines Corporation (NASDAQ:BPMC) Given Consensus Rating of "Hold" by BrokeragesAugust 18 at 2:57 AM | americanbankingnews.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Blueprint Medicines Corporation (NASDAQ: BPMC)July 14, 2025 | globenewswire.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.August 20 at 2:00 AM | Paradigm Press (Ad)BPMC Blueprint Medicines Corporation - Seeking AlphaJuly 1, 2025 | seekingalpha.comBlueprint Medicines Corporation (BPMC) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comBlueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic MastocytosisJune 24, 2025 | msn.comBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint ...June 22, 2025 | morningstar.comMBLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMCJune 20, 2025 | businesswire.comSee More Headlines BPMC Stock Analysis - Frequently Asked Questions How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corporation (NASDAQ:BPMC) posted its quarterly earnings data on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.32. The company's quarterly revenue was up 55.5% on a year-over-year basis. Read the conference call transcript. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Top institutional investors of Blueprint Medicines include State Street Corp (3.45%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.65%), Geode Capital Management LLC (2.39%) and Norges Bank (1.66%). Insiders that own company stock include Kate Haviland, Jeffrey W Albers, Fouad Namouni, Christina Rossi, Tracey L Mccain, Percy H Carter, Michael Landsittel, Debra Durso-Bumpus, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley. View institutional ownership trends. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/01/2025Today8/20/2025Next Earnings (Estimated)10/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPMC CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees640Year Founded2011Price Target and Rating Average Price Target for Blueprint Medicines$130.00 High Price Target$135.00 Low Price Target$119.00 Potential Upside/Downside+0.4%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.09 million Net Margins-27.70% Pretax Margin-27.38% Return on Equity-64.60% Return on Assets-17.22% Debt Debt-to-Equity Ratio1.01 Current Ratio2.80 Quick Ratio2.75 Sales & Book Value Annual Sales$562.12 million Price / Sales14.87 Cash FlowN/A Price / Cash FlowN/A Book Value$4.70 per share Price / Book27.54Miscellaneous Outstanding Shares64,582,000Free Float61,863,000Market Cap$8.36 billion OptionableOptionable Beta0.89 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:BPMC) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.